Condition: Neuroendocrine Tumors · Gastroenteropancreatic Neuroendocrine Tumor · Sponsor: Methodist Health System
The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.
This description comes directly from the study's public registry record.
Colette N Ndjom, MS · 214-947-1280 · clinicalresearch@mhd.com
Jennifer Kirchner · 214-947-1280 · clinicalresearch@mhd.com
Always discuss trial participation with your own doctor first.
| Clinical Research Institute at Methodist Health System | Dallas, Texas, United States | Recruiting |
| Methodist Dallas Medical Center | Dallas, Texas, United States | Enrolling By Invitation |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04090034